Skip to main content
. Author manuscript; available in PMC: 2017 Dec 26.
Published in final edited form as: Oncogene. 2017 Jun 26;36(43):5939–5947. doi: 10.1038/onc.2017.197

Figure 7. Inhibition of PARP-1 activity partially restores cisplatin sensitivity in MKP-1-overexpressing ovarian cancer cells.

Figure 7

MKP-1-overexpressing or control vector TOV112D cells were left untreated or exposed to cisplatin (Cis) at 1 μg/mL, 20 μM PARP inhibitor ABT888 (ABT), or cisplatin plus ABT888 (ABT+Cis) for 3 days, and cell viability was determined by MTT assays.